AgomAb Therapeutics NV (NASDAQ:AGMB) Given Average Rating of “Moderate Buy” by Analysts

AgomAb Therapeutics NV (NASDAQ:AGMB) has earned an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $32.75.

Several research firms have issued reports on AGMB. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a report on Wednesday, March 4th. Leerink Partners began coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 price objective on the stock. Morgan Stanley began coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price objective on the stock. HC Wainwright began coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price objective on the stock.

AgomAb Therapeutics Stock Performance

NASDAQ:AGMB opened at $13.81 on Monday. The stock’s fifty day moving average price is $11.19. AgomAb Therapeutics has a 52-week low of $8.75 and a 52-week high of $17.45.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.